Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose 2.4% on Thursday . The company traded as high as $14.28 and last traded at $14.22, with a volume of 236,805 shares trading hands. The stock had previously closed at $13.88.

LXRX has been the subject of a number of research reports. Stifel Nicolaus boosted their target price on shares of Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Wedbush boosted their target price on shares of Lexicon Pharmaceuticals from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, May 31st. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Needham & Company LLC reiterated a “buy” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, August 11th. Finally, Citigroup Inc. initiated coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 2nd. They set a “buy” rating and a $21.00 target price for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $20.07.

The company has a 50-day moving average of $15.46 and a 200 day moving average of $13.48. The company’s market cap is $1.48 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. The business had revenue of $20.10 million for the quarter, compared to analysts’ expectations of $12.36 million. The business’s revenue was up 5186.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.27) earnings per share. Equities research analysts anticipate that Lexicon Pharmaceuticals Inc. will post ($1.54) earnings per share for the current year.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.